Nantahala Capital Management LLC Sells 39,856 Shares of InspireMD, Inc. (NYSE:NSPR)

Nantahala Capital Management LLC trimmed its position in InspireMD, Inc. (NYSE:NSPR) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,026,600 shares of the company’s stock after selling 39,856 shares during the quarter. Nantahala Capital Management LLC owned 8.13% of InspireMD worth $5,057,000 at the end of the most recent reporting period.

Separately, Rosalind Advisors Inc. grew its stake in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares during the period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

NSPR has been the topic of several recent analyst reports. Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th. StockNews.com initiated coverage on shares of InspireMD in a research report on Tuesday. They issued a “sell” rating on the stock.

InspireMD Stock Down 2.9 %

NSPR stock opened at $2.67 on Tuesday. InspireMD, Inc. has a twelve month low of $1.81 and a twelve month high of $3.85. The company has a market cap of $66.56 million, a P/E ratio of -3.51 and a beta of 0.90. The business’s fifty day moving average is $2.82 and its 200-day moving average is $2.52.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. During the same quarter last year, the firm earned ($0.24) EPS. Research analysts anticipate that InspireMD, Inc. will post -0.82 earnings per share for the current fiscal year.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.